Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BB-1701 plus sintilimab in HER2-expressing or HER2-mutant advanced solid tumors
CTR20243614Phase 2Active
- Sponsor
- Bliss Biopharmaceutical
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BB-1701, sintilimab in breast cancer, non-small cell lung cancer (NSCLC), Nonhematologic neoplasms, sponsored by Bliss Biopharmaceutical. Started Dec 2024; status: active.
02
Drugs
BB-1701sintilimab
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20243614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243614.